Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

February 19, 2026

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

January 29, 2026

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

Enveric Biosciences Announces Patent Issuance

December 29, 2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

December 12, 2025

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

December 11, 2025

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

December 9, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

December 4, 2025

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

November 26, 2025

1
2
3
…
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.